Clinical

DAPA-CKD Analysis Suggests Farxiga is Safe, Effective in More Advanced Chronic Kidney Disease

July 24, 2021

Data from a prespecified analysis of DAPA-CKD examining effects of dapagliflozin in patients with stage 4 CKD suggests the impact of the SGLT2 inhibitor in these patients was similar to those seen in the overall trial.

Nutrition as a Pillar of Preventive Cardiology and Other Highlights from ASPC 2021, with Martha Gulati, MD

July 23, 2021

Martha Gulati, MD, discusses nutrition and its role in preventive cardiology as well as other highlights from the American Society for Preventive Cardiology's 2021 Virtual Summit.

With Implantable Cardioverter-Defibrillators, Every 10-Minute Increase in Physical Activity Reduces Mortality Risk by 1.1%

July 22, 2021

Analysis of more than 40k Medicare beneficiaries suggests increased physical activity, whether it occurs as part of a rehabilitation or not, was associated with decreased risk of all-cause mortality and hospitalizations for heart failure in patients who recently received an implantable cardioverter-defibrillator.

More Than A Heart and Lungs in The Chest, with Paul Thompson, MD

July 22, 2021

In his most recent column, Dr. Paul Thompson offers perspective on why he feels clinicians should consider performing a chest x-ray in patients with dyspnea or frequent palpitations, but no history of lung disease and a normal cardiac work-up.

Tenapanor Nixed By FDA, Citing Deficiencies in Application

July 21, 2021

Citing deficiencies within the New Drug Application submitted for tenapanor for use in patients with chronic kidney disease, the US FDA issued a letter to Ardelyx noting these deficiencies “preclude discussion” related to labeling and post-marketing requirements.

No Evidence Coffee Consumption Increases Risk of Arrhythmias, UCSF Study Finds

July 20, 2021

Analysis of data from the UK Biobank cohort suggests consumption of coffee was not linked to an increased risk of arrhythmias, with some evidence indicating habitual use was linked to a decrease in incidence of atrial fibrillation or flutter and supraventricular tachycardia.

Abelacimab Demonstrates Potential of Factor XI Inhibition in Preventing Blood Clots

July 19, 2021

A 412-patient trial comparing 3 dosing regimens of abelacimab versus enoxaparin, results indicate all 3 regimens of abelacimab demonstrated noninferiority against enoxaparin and 2 of the 3 demonstrated superiority against the current standard of care.